Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Long-Term Debt Repayments (2017 - 2025)

Plus Therapeutics (PSTV) has disclosed Long-Term Debt Repayments for 10 consecutive years, with $3.7 million as the latest value for Q1 2025.

  • On a quarterly basis, Long-Term Debt Repayments rose 821.14% to $3.7 million in Q1 2025 year-over-year; TTM through Sep 2025 was $3.7 million, a 15.8% decrease, with the full-year FY2024 number at $4.0 million, up 148.51% from a year prior.
  • Long-Term Debt Repayments was $3.7 million for Q1 2025 at Plus Therapeutics, up from $3.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $3.7 million in Q1 2025 to a low of $402000.0 in Q1 2022.
  • A 4-year average of $992272.7 and a median of $402000.0 in 2022 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: changed 0.0% in 2023, then skyrocketed 821.14% in 2025.
  • Plus Therapeutics' Long-Term Debt Repayments stood at $402000.0 in 2022, then changed by 0.0% to $402000.0 in 2023, then skyrocketed by 794.03% to $3.6 million in 2024, then grew by 3.03% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Long-Term Debt Repayments are $3.7 million (Q1 2025), $3.6 million (Q2 2024), and $402000.0 (Q1 2024).